Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) Research & Development (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Research & Development for 3 consecutive years, with $17.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 27.61% to $17.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $69.5 million, a 38.17% increase, with the full-year FY2025 number at $69.5 million, up 38.17% from a year prior.
  • Research & Development was $17.0 million for Q4 2025 at Artiva Biotherapeutics, down from $17.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $17.9 million in Q2 2025 to a low of $11.2 million in Q1 2024.
  • A 3-year average of $14.8 million and a median of $13.5 million in 2024 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: increased 3.51% in 2024, then soared 52.85% in 2025.
  • Artiva Biotherapeutics' Research & Development stood at $13.1 million in 2023, then grew by 1.93% to $13.3 million in 2024, then rose by 27.61% to $17.0 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Research & Development are $17.0 million (Q4 2025), $17.6 million (Q3 2025), and $17.9 million (Q2 2025).